FY2026 EPS Forecast for Ionis Pharmaceuticals Cut by Analyst

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Equities research analysts at Leerink Partnrs dropped their FY2026 earnings per share (EPS) estimates for shares of Ionis Pharmaceuticals in a research note issued on Monday, February 24th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($3.25) for the year, down from their previous estimate of ($3.24). The consensus estimate for Ionis Pharmaceuticals' current full-year earnings is ($3.50) per share. Leerink Partnrs also issued estimates for Ionis Pharmaceuticals' FY2027 earnings at ($1.62) EPS.

Several other research firms have also recently issued reports on IONS. William Blair reaffirmed an "outperform" rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Citigroup lowered their price objective on shares of Ionis Pharmaceuticals from $67.00 to $64.00 and set a "buy" rating on the stock in a research note on Thursday, February 20th. Wells Fargo & Company reduced their target price on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an "overweight" rating for the company in a report on Thursday, November 7th. StockNews.com lowered shares of Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday, November 12th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $70.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday, February 20th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Ionis Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $60.00.

Remove Ads

Ionis Pharmaceuticals Stock Down 1.8 %

NASDAQ:IONS traded down $0.59 during mid-day trading on Thursday, hitting $32.60. The company had a trading volume of 1,512,215 shares, compared to its average volume of 1,666,279. The firm has a market capitalization of $5.18 billion, a price-to-earnings ratio of -10.72 and a beta of 0.34. Ionis Pharmaceuticals has a 1 year low of $30.23 and a 1 year high of $52.34. The business has a fifty day simple moving average of $33.18 and a 200-day simple moving average of $37.71. The company has a current ratio of 8.47, a quick ratio of 8.82 and a debt-to-equity ratio of 2.12.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The company reported ($0.66) earnings per share for the quarter, beating analysts' consensus estimates of ($1.12) by $0.46. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. The business had revenue of $227.00 million during the quarter, compared to analyst estimates of $140.97 million. During the same quarter in the previous year, the business posted $0.12 earnings per share. The company's revenue was down 30.2% on a year-over-year basis.

Insider Activity at Ionis Pharmaceuticals

In other news, EVP Patrick R. O'neil sold 1,207 shares of the firm's stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $32.35, for a total value of $39,046.45. Following the transaction, the executive vice president now directly owns 56,245 shares of the company's stock, valued at approximately $1,819,525.75. This trade represents a 2.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Eric Swayze sold 7,154 shares of the firm's stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $32.84, for a total value of $234,937.36. Following the sale, the executive vice president now directly owns 45,670 shares of the company's stock, valued at approximately $1,499,802.80. This trade represents a 13.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 111,816 shares of company stock worth $3,603,914 in the last quarter. 2.71% of the stock is owned by company insiders.

Institutional Trading of Ionis Pharmaceuticals

Several institutional investors have recently modified their holdings of the stock. Signaturefd LLC lifted its stake in Ionis Pharmaceuticals by 160.0% in the 4th quarter. Signaturefd LLC now owns 949 shares of the company's stock valued at $33,000 after buying an additional 584 shares in the last quarter. Huntington National Bank grew its position in Ionis Pharmaceuticals by 193.5% in the 4th quarter. Huntington National Bank now owns 951 shares of the company's stock worth $33,000 after purchasing an additional 627 shares during the last quarter. Lindbrook Capital LLC lifted its position in Ionis Pharmaceuticals by 183.8% in the fourth quarter. Lindbrook Capital LLC now owns 1,036 shares of the company's stock worth $36,000 after purchasing an additional 671 shares during the period. Capital Performance Advisors LLP bought a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter worth $40,000. Finally, Prospera Private Wealth LLC acquired a new position in Ionis Pharmaceuticals during the third quarter valued at $42,000. Hedge funds and other institutional investors own 93.86% of the company's stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.